← SynDRA
BGT-226 FREE BASE
SynDRA canonical compound SYN0037984 — structure-anchored drug synonym record
| Clinical phase | Phase 1/Phase 2 |
|---|
| Primary target(s) | MTOR | PIK3CA | PIK3CB | PIK3CG |
|---|
| Mechanism of action | PI3K inhibitor |
|---|
All known targets
- MTOR
- PIK3CG
- PIK3CA
- PIK3CB
- PIK3CD
- PIK3R1
- PIK3R2
- PIK3R3
- PIK3R5
Mechanisms of action (all sources)
- MTOR inhibitor
- Serine/threonine-protein kinase mTOR inhibitor
- PIK3R1 INHIBITOR
- PIK3CB INHIBITOR
- PIK3CG INHIBITOR
- PIK3CA INHIBITOR
- PIK3R2 INHIBITOR
- PIK3CD INHIBITOR
- PIK3R5 INHIBITOR
- PIK3R3 INHIBITOR
- PI3K inhibitor
- MTOR MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CLK1
- MELK
- FECH
- DYRK1A
- GSK3A
- PIK3C3
- CSNK2A2
- PIK3CD
- TP53RK
- SYK
- MYLK3
- PIP4K2C
- PCYT1A
- PDGFRB
- PAK6
- PASK
- PAK4
- PAK2
- PAICS
- OPA1
- OLA1
- NUAK2
- PDXK
- AAK1
- PEBP1
- PFKP
- PGRMC1
- PHKG2
- PIM1
- PIM2
- PKMYT1
- PKN1
- PKN2
- PLK1
- PLK4
- PRKAA1
- PRKACA
- PRKACB
- NTRK1
- NEK9
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ATXN2
- CP3A7
- HLAB
- IFNB1
- IFNG
- KSYK
- MITF
- NSD2
- NTM1A
- NTMT1
- PARP1
- TFE3
Cross-references
Synonyms
- BGT-226
- BGT226 free base
- BGT 226
- ZXE7F2GMJJ
- UNII-ZXE7F2GMJJ
- C28H25F3N6O2
- BGT-226 (maleate salt)
- NPV-BGT226
- SCHEMBL146939
- GTPL7951
- orb1301099
- SCHEMBL29351405
- SCHEMBL29388241
- SCHEMBL29388607
- CHEBI:71967
- BMMXYEBLEBULND-UHFFFAOYSA-N
- BDBM185147
- EX-A3430
- HY-13334A
- MFCD22376639
- NSC773095
- NSC799358
- T6072L
- AKOS037643410
- EBC-428047
- NSC-773095
- NSC-799358
- SDCCGSBI-0654465.P001
- NCGC00346681-01
- NCGC00346681-09
- NCGC00346681-10
- NCGC00346681-11
- NCGC00346681-13
- AS-16313
- DA-18144
- US9284315, BGT-226
- CS-0034414
- G14161
Look up BGT-226 FREE BASE in the interactive SynDRA portal →